Amgen Inc. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Amgen Inc. with three other
pharmaceutical manufacturers in North America:
Gilead Sciences, Inc.
sales of $24.69 billion
of which 100%
was discovery, development and commercializa),
DuPont de Nemours Inc
of which 30%
was Nutrition & Biosciences), and
Eli Lilly and Company
of which 29%
was Oncology-Verzenio & Other).
Amgen Inc. reported sales of $25.42 billion
December of 2020.
increase of 8.8%
versus 2019, when the company's sales were $23.36 billion.
Sales of Other Products saw an increase
that was more than double the company's growth rate: sales were up
32.6% in 2020, from
$4.96 billion to $6.57 billion.
Not all segments of Amgen Inc. experienced an increase in sales in 2020:
sales of Neulasta fell 28.8% to $2.29 billion.
Amgen Inc. also experienced decreases in sales in
Enbrel (down 4.4% to $5.00 billion)
Xgeva (down 1.9% to $1.90 billion)
Aranesp (down 9.3% to $1.57 billion)